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Abstract
Background: Identifying men for a repeat prostate biopsy is a conundrum to urologists. Risk calculators (RCs) such
as the European Randomized Study of Screening for Prostate Cancer (ERSPC) RCs have been developed to predict
the outcome of prostate biopsies and have been shown to improve diagnostic accuracy compared to PSA alone.
However, it was recently shown that the outcome for high-grade prostate cancer (PCa) upon biopsy tended to be
underestimated in men with previous negative biopsies using ERSPC RC model 4. For these men, an individualized
approach combining the clinical information with the outcome of biomarker-related urine tests may help to make
a more informed decision.
Case presentation: Two men, aged 66 and 69 respectively when presented in the clinic, show the typical dilemma
of urologist and patient for electing repeat prostate biopsy. Both men had normal DRE findings, did not have a
family history of PCa, presented with serum PSA values between 3 and 10 ng/ml and the first biopsies were
negative for disease. The ERSPC RC4 did not indicate a biopsy in these men. The urinary molecular biomarker-based
test for HOXC6 and DLX1, combining biomarker-expression profiling with clinical risk factors, resulted in SelectMDx
Risk scores for these men that were higher than the cut-off of the test. Based on this outcome, mpMRI was
performed with an outcome of PI-RADS ≥4 in both men. Histopathological evaluation of TRUS-guided biopsies
confirmed high-grade PCa.
Conclusions: The urinary molecular biomarker-based risk score played a pivotal role in the diagnosis of clinically
significant PCa whereas ERSPC RC4 outcome would not have indicated further diagnostic follow-up in these two
cases. The timely diagnosis was shown to be crucial for the curative treatment by radical retropubic prostatectomy
and the potential life-years gained for these two vital males.
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Background
Early detection of significant prostate cancer (PCa) in-
creases the curative success rate. Histopathologic evaluation
of transrectal ultrasound -guided systematic core needle bi-
opsy (TRUS-Bx) tissue is the main method to diagnose the
disease, and the decision to take a biopsy is made in case of
serum prostate-specific antigen (PSA) > 3 ng/ml and/or an
abnormal digital rectal examination (DRE). For more than
30 years, serum PSA has been considered the most valuable
tool in early detection of the disease, but its low specificity
for PCa has resulted in the detection and treatment of slow
growing PCa’s that will not cause harm in a man’s lifetime
and a negative biopsy rate of 70% in men with benign pros-
tate diseases such as benign prostatic hyperplasia (BPH) or
prostatitis. The chance of missing a cancer upon TRUS-Bx
is ~ 25% because it is systematic, non-targeted, and directed
towards the peripheral gland. Therefore, repeat biopsies are
warranted in cases with persistent indication (abnormal
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DRE, elevated PSA value and/or histopathological findings
suggestive of malignancy at the initial biopsy) [1, 2]. In the
second set of biopsies, a detection rate of approximately
10–35% has been reported [2]. For a patient, these repeat
biopsies will result in additional anxiety, physical discomfort
and complication risk. The proportion of men undergoing
biopsy who experienced non-sepsis infectious complica-
tions is ~ 18, and 3% of men experience sepsis that requires
hospitalization [3, 4]. Hence a physician’s and patient’s deci-
sion to elect for prostate biopsy is guided by the fear of
missing a clinically significant PCa that may become life-
threatening when left untreated.
Currently, the decision to perform prostate biopsies is
based on clinical judgement of the physician guided by
European Association of Urology (EAU) recommenda-
tions which incorporates the results of PSA testing, DRE
outcome and/or the additional diagnostic options such
as a risk calculator (RC), an additional serum- or urine-
based test or imaging [5].
Multiparametric MRI (mpMRI) is the most accurate
imaging modality for localization of PCa. The use of
mpMRI before biopsy could indicate whether the patient
requires a biopsy because of a significant cancer identified
on mpMRI or whether biopsy could be avoided. The EAU
guideline committee recommends the use of mpMRI be-
fore repeat biopsy to allow targeted biopsies of suspicious
lesions in addition to standard biopsies. However, the risk
of missing 16.2 to 39.7% clinically significant prostate can-
cers using mpMRI targeted biopsy for mpMRI Prostate
Imaging Reporting and Data System outcome (PI-RADS)
≥3 stresses the need to use RCs or biomarker-based tests
for an improved risk stratification for a repeat biopsy [6].
The Rotterdam arm of the European Randomized Study
of Screening for Prostate Cancer (ERSPC) developed sev-
eral RCs, using the clinical data and prostate biopsy out-
come from thousands of previously unscreened men and
men with previous negative prostate biopsy, calculating
the chance of finding PCa on a TRUS-guided biopsy. The
ERSPC RC4 is designed and used by urologists to deter-
mine the likelihood of cancer in repeat biopsy. Recently,
external validation of the ERSPC RC3 and ERSPC RC4 in
a contemporary Dutch clinical cohort using a biopsy
scheme showed that the RCs performed well, but that in
the repeat biopsy setting the outcomes for PCa risk and
clinically significant PCa tended to be underestimated for
ERSPC RC4 [7]. For men with a previous negative biopsy,
an individualized approach combining the clinical infor-
mation with the outcome of biomarker-related urine tests
may help to make a more informed decision.
Recently, gene expression profiling was used to iden-
tify diagnostic and predictive biomarkers for high grade
PCa followed by a stepwise biomarker selection and test-
ing of a gene panel consisting of Homeobox C6 (HOXC6),
Tudor domain containing 1 (TDRD1) and Distal-less
homeobox 1 (DLX1) in post-DRE urine sediments for the
diagnosis of biopsy Gleason score ≥ 7 PCa [8]. Using
whole urine as a substrate, the combination of HOXC6
and DLX1 had the best performance to predict high-grade
PCa on biopsy which was successfully validated in an
independent cohort [9]. DLX1 and HOXC6 are involved in
prostate cancer progression and are associated with high-
grade PCa [10, 11]. When this patient-specific biomarker
expression profile is combined with traditional clinical risk
factors, a likelihood risk score is obtained to detect clinic-
ally significant PCa (Gleason score (GS) ≥7) upon biopsy
[9]. It was shown that SelectMDx risk score correlates
with PI-RADS ≥3 and can contribute to the stratification
of patients for mpMRI [12].
Clinical utility of this urinary molecular biomarker-
based test, SelectMDx® for Prostate Cancer (hereafter
SelectMDx), was evaluated in 34 men with a previous
negative biopsy identified in routine clinical practice,
with no study-specific visits or interventions. In five
men, both the ERSPC RC4 and the SelectMDx test indi-
cated the need for biopsy. Three men (60%) underwent
prostate biopsies and in two significant PCa was found.
Of the 14 men who were low risk for both the ERSPC
RC4 and SelectMDx test, two (14%) underwent negative
biopsies. The SelectMDx test indicated a risk for high-
grade PCa upon biopsy in 15 ERSPC RC4 low risk men.
Six of these men (40%) underwent prostate biopsy and in
three men significant PCa was confirmed (see Table 1).
This report describes two cases, identified in the latter
group, in which the SelectMDx test was pivotal in the
early diagnosis of clinically significant PCa.
Case presentation 1
In January 2015, a 66-year-old male presented at the Ur-
ology ward of the LangeLand Hospital with a serum PSA
of 6.4 ng/ml which was elevated compared to the upper
limit of normal serum PSA of 4.5 ng/ml of men of his
age. The patient had no paternal history of PCa and had
no urinary complaints. The physical examination of the
prostate gland (DRE) by the physician was normal. Pros-
tate volume by TRUS was 35 cm3 and TRUS findings
were normal. TRUS-Bx was performed (5 left and 5
right). Biopsies were negative for malignancy.
In June 2015, the serum PSA increased to 7.2 ng/ml and
there was no sign of a urinary tract infection. Therefore,
the physician used ERSPC RC4 with TRUS or DRE (www.
Table 1 Concordance table urine biomarker test versus ERSPC R4
Previous Negative Biopsy Cohort ERSPC R4 (+) ERSPC R4 (−) Total
SelectMDx test (+) 5 15 20
SelectMDx test (−) 0 14 14
Total 5 29 34
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prostatecancer-riskcalculator.com) containing PSA, DRE
(normal/abnormal), TRUS (normal/abnormal), TRUS-
assessed volume and biopsy history. This model can be
used for biopsy-naïve men and for men that have had a
previous biopsy with a benign result. After entering the
available data, the risk of having PCa or high-grade PCa is
displayed. The ERSPC RC4 showed that this man’s risk
for PCa and high-grade PCa was 17 and 3%, respectively.
Prostate biopsy is indicated when the ERSPC RC4 risk for
PCa is > 20% and if the risk for PCa is between 12.5 and
20%, in combination with a risk for high-grade disease of
> 4%. Biopsy is not indicated when the risk for PCa on bi-
opsy is < 12.5%. Based on this outcome, patient and phys-
ician elected for PSA follow-up.
Six months later, serum PSA increased to 10.8 ng/ml.
At that time the physician used the urine biomarker test,
SelectMDx test (MDxHealth B.V.). After DRE, 16 ml of
first void urine was collected from the patient using the
urine sample collection kit (Catalogue number UrNCSE1,
MDxHealth B.V.). Using this kit, the urinary RNA
was immediately preserved in 4 ml of preservative. On
the day of collection, samples were shipped at room
temperature to the clinical diagnostic laboratory (Nijmegen,
the Netherlands), after which the samples were stored at −
20 °C prior to analysis. Reverse transcriptase PCR (RT-
PCR) was used to determine the amount of HOXC6 and
DLX1 mRNA in the patient’s urine. The patient-specific
biomarker expression profile was then combined with the
patient’s traditional clinical risk factors, including PSA,
DRE, prostate volume, age and family history using a dedi-
cated algorithm [9]. The outcome is a patient-specific
SelectMDx Risk score. If the SelectMDx Risk Score is below
the cut-off point of − 2.8 a very low risk report will be gen-
erated with a negative predictive value (NPV) of 98% for
Gleason score ≥ 7 PCa. A Risk Score higher or equal to this
cut-off point is converted into the likelihood that subse-
quent biopsy will detect prostate cancer or high-grade pros-
tate cancer. For this man, the likelihood for having PCa was
49% and the chance of having high-grade disease was 22%.
Based on this outcome, a prostate MRI was done in
January 2016 (see Fig. 1). The outcome was PI-RADS 5
in the left peripheral zone of the prostate. TRUS-Bx
revealed Gleason score 3 + 4 = 7 PCa in 4 of 5 biopsies
taken from the left peripheral zone.
In May 2016, the patient underwent a robot-assisted
radical retropubic prostatectomy (RRP). The prostate
specimen was found to contain extensive carcinoma with
a Gleason score 3 + 4 = 7 in both lobes (pT2c), margins
and lymph nodes were clear. As part of the follow-up,
the PSA is still < 0.01 ng/ml.
Case presentation 2
In September 2012, a 69-year-old male with an unknown
paternal history for PCa came to the Urology ward of
the LangeLand hospital with an increased serum PSA
level of 8.7 ng/ml. He had a prostate volume of 43.5 cm3,
a normal DRE outcome and normal TRUS findings.
TRUS-Bx (5 left and 5 right) were negative for malig-
nancy. In October 2013, his PSA increased to 26.6 ng/
ml. This marked elevation in serum PSA was likely
caused by acute prostatitis for which the urologist pre-
scribed antibiotics. Under antibiotics his PSA decreased
to 4.3 ng/ml at the beginning of 2014.
In December 2015, the PSA was 15.4 ng/ml. The
ERSPC RC4 showed that the man’s risk for PCa and
high-grade PCa was 16 and 4% respectively. Based on
this outcome there was no clear biopsy indication. The
SelectMDx test was performed and for this man the like-
lihood for having PCa was 39% and the chance of having
high-grade PCa was 14%. Based on this outcome, a pros-
tate MRI was performed indicating a PI-RADS 4 in the
right peripheral zone of the prostate. However, the three
MRI-guided biopsies were negative for PCa.
In August 2016, the PSA increased to 20 ng/ml. Based
on the prostatitis history and the negative prostate biop-
sies antibiotics was prescribed, but under treatment the
PSA increased to 21.4 ng/ml. Since the SelectMDx test
indicated an elevated risk for high-grade PCa for this pa-
tient, the urologist decided to repeat TRUS-Bx in Octo-
ber 2016. This resulted in the diagnosis of Gleason score
3 + 4 = 7 and 10% cribriform intraductal carcinoma in 2
out of 5 biopsies in the right peripheral zone of the pros-
tate. The presence of intraductal carcinoma is usually as-
sociated with adverse prognostic parameters (e.g. high-
grade Gleason score, large tumour volume, extra-prostatic
extension and seminal vesicle invasion) and correlates
with worse disease outcomes.
In December 2016, the patient underwent robot-assisted
RRP. The prostate specimen was found to contain 2
tumours in the right peripheral zone of the prostate: one
Gleason score 4 + 4 = 8 and one Gleason score 3 + 3 = 6
PCa (pT2a), margins and lymph nodes were clear and
PSA nadir was < 0.01 ng/ml.
Discussion and conclusions
Identifying men for a repeat prostate biopsy is a conun-
drum to urologists. Following negative biopsy, men fre-
quently exhibit persistently elevated PSA, raising concerns
for missed diagnosis of an aggressive PCa. Decision mak-
ing regarding repeat biopsies is a balance between avoid-
ing anxiety and risk of complications associated with the
procedure and the fear for missing a clinically significant
cancer. Furthermore, there is the risk with repeat biopsy
of detecting and treating low-grade and low volume PCa
that is not life-threatening. In this report, two cases are
described that show the typical dilemma of urologist and
patient within daily clinical practice for electing repeat
prostate biopsy. Here the SelectMDx test played a pivotal
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role in the timely diagnosis of clinically significant PCa
which was crucial for the curative treatment by RPP and
the potential life-years gained for these vital males.
The decision to perform prostate biopsies is guided by
EAU recommendations which incorporates mpMRI, RC
and/or an additional serum- or urine-based test (e.g. based
on HOXC6 and DLX1) to individualize the need for a re-
peat biopsy [5]. In the second case, mpMRI targeted biop-
sies were performed that did not find the tumour. Recently,
Pepe and collegues showed that if only targeted biopsy was
performed when mpMRI showed a suspicious lesion (PI-
RADS≥3), the number of biopsies could potentially have
been reduced by 50%. However, 16.2–39.7% of the clinically
significant prostate cancers would be missed using this
approach [6]. Therefore, targeted biopsies should be done
together with mapping biopsies and for risk-stratification
mpMRI should be combined with an RC or biomarker-
based test as the EAU guideline committee recommends.
Risk calculators are models, which take a patient’s risk
factors, combines them all into an equation and assigns
a level of risk for having a disease. Several RCs were de-
veloped based on the Rotterdam arm of the ERSPC,
using the clinical data and prostate biopsy outcome from
3624 previously unscreened men and 2896 men with
previous negative prostate biopsy [13]. For the men
described in the presented cases, the physicians used
ERSPC RC4 containing PSA, DRE (normal/abnormal),
TRUS (normal/abnormal), TRUS-assessed volume and
Fig. 1 In November 2015, the patient of case 1 had a PSA level of 10.8 ng/ml and was referred for multiparametric prostate 3 T MRI for diagnostic
purposes because the urinary biomarker-based risk score was 22% for high-grade PCa indicating the need for prostate biopsy. a An axial T2-
weighted image shows a lesion on the left peripheral zone at the prostate base anterior side (red circle). b An axial diffusion-weighted image
(DWI) shows an area of increased signal at the left peripheral zone. c An axial apparent diffusion coefficient (ADC) map shows a corresponding
area of low ADC value (red circle). d A colorized perfusion map created from dynamic contrast-enhanced MRI (DCE-MRI) acquisition shows
corresponding abnormal enhancement kinetics at the same location. All sequences identified the same region in the left anterior peripheral zone.
The PI-RADS 5 outcome confirmed the biopsy indication of the urinary biomarker-based test outcome. TRUS-guided biopsies from that region
confirmed high-grade Gleason 3 + 4 = 7 PCa
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biopsy history. For both men, the ERSPC RC4 indicated
not to perform a prostate biopsy.
Recently, in a contemporary Dutch cohort, the ERSPC
PCa probability threshold of ≥20% was shown to be
acceptable for the biopsy-naïve men, missing only 2% of
significant cases while saving 20% of prostate biopsies
[7]. However, in men with previous negative biopsies,
the ERSPC RC4 underestimated the outcomes for PCa
and significant PCa. At this threshold, the RC4 would
have missed 23% of significant cases while saving 47% of
prostate biopsies. Gayet et al. showed that a threshold of
≥10% for PCa and > 2% for significant PCa would have
been most optimal for men with previous negative biop-
sies, missing only 2% of significant cases and saving 21%
of prostate biopsies. A possible factor attributing to the
underestimation could be the fact that men with a previ-
ous negative biopsy were a higher risk cohort compared
with the ERSPC cohort in which every man with an
elevated serum PSA > 3 ng/ml at repeat screening was
biopsied again within 4 years after initial biopsy [7].
An improvement of RCs would be the inclusion of
biomarkers that are measured in body fluids of a patient.
Prostate cells, cancerous or benign, shed cellular content
such as cell-free nucleic acid in the urine. Therefore,
urine as liquid biopsy offers an attractive alternative for
tissue biopsies due to the direct contact of the urinary
flow with draining of the genitourinary organs such as
the prostate [14]. By combining the patient-specific bio-
marker expression profile with the clinical information
of the patient, the resulting individualized risk score will
allow the physician and patient to make the most in-
formed choice about undergoing or delaying a prostate
biopsy. Van Neste et al. already showed that this newly
developed risk score outperformed the Prostate Cancer
Prevention Trial Risk Calculator (PCPTRC) resulting in
an improved patient risk stratification for high-grade
PCa and biopsy decision-making [9].
The two cases presented here were identified in routine
clinical practice in a Dutch hospital, with no study-specific
visits or interventions. The novel urine biomarker test led
to the use of prostate MRI prior to prostate biopsy. A re-
cent systematic review on the NPV of mpMRI in exclud-
ing PCa at biopsy showed that the NPV depends on the
prevalence of PCa [15]. At an overall PCa prevalence of
30% the NPV of mpMRI could be 88%, but when com-
pared to the prevalence of 40% in the Van Neste et al
study, the NPV of mpMRi would decrease to 82% [15].
Recently, it was shown that there is a correlation between
the urine biomarker risk score and mpMRI outcomes
[12]. Since the NPV of the urine-based genetic test is 98%
and the risk score correlates with mpMRI outcomes, this
urine biomarker test may become an important decision
tool, not just for biopsy, but to risk stratify patients for
mpMRI as well.
Recently, Cucchiara et al. showed that genomic bio-
markers in combination with clinical and pathological
variables have improved the detection, prognosis, and
risk evaluation of PCa [16]. The SelectMDx test is a use-
ful tool to reduce the number of unnecessary biopsies
and stratify low-risk from high-risk tumors. Cost effect-
iveness studies have shown that quality-adjusted survival
can be improved using this test by decreasing the num-
ber of biopsies performed and by not treating indolent
tumors [17–19]. We acknowledge that the here described
data only represents two cases and that no firm claims can
be made based on these results. Large-scale case-controlled
studies should confirm the applicability and reliability of
using the SelectMDx test over the ERSPC RC4 in risk
stratification for repeat biopsy.
The case reports on two men with persistent suspicion
of PCa but negative prostate biopsy stress the need to
use all the tools that EAU guidelines propose (mpMRI,
RCs, biomarker-based tests) to individualize the need for
biopsy. Although RCs are recommended and commonly
used by urologists to predict repeat biopsy outcome, the
fact that there may be an underestimate of the outcomes
for high-grade PCa stresses the need to use multivariate
risk stratification tools (e.g. combine the clinical infor-
mation with biomarkers for high-grade disease) in order
to make a more informed repeat biopsy decision. These
two routine clinical practice examples demonstrate that
the urine biomarker test for HOXC6 and DLX1, combin-
ing clinical data with biomarkers detected in urine from
a patient, offers an easy and individualized tool for strati-
fying men for mpMRI and biopsy.
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